Phase I, first-in-human, open-label, dose-escalation study of U3-1565, a fully human anti-HB-EGF monoclonal antibody, in patients with advanced solid tumors.
Kathleen N. Moore
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose
Anthony J. Olszanski
No relevant relationships to disclose
Madhuri Desai
No relevant relationships to disclose
Mendel Jansen
No relevant relationships to disclose
Richard David Scheyer
No relevant relationships to disclose
Giorgio Senaldi
No relevant relationships to disclose
Patricia LoRusso
No relevant relationships to disclose